Drug intelligence / Profile preview

Fetal ventral mesencephalic cells

Development stage: Unknown
Modality: Cell Therapies
Administration: Intracerebral Transplantation

Overview

Fetal ventral mesencephalic cells are dopamine-rich cells derived from the ventral mesencephalon of fetuses. These cells have been explored for their potential in treating Parkinson's disease by replacing or repairing damaged dopamine-producing neurons in the brain. The transplantation involves injecting these cells into the brain, specifically into the striatum, where they can help restore dopamine levels and improve motor function. The main mechanism of action involves the release of dopamine by these grafted cells, thereby compensating for the loss of native dopamine-producing neurons in Parkinson's disease. This approach is considered a form of **cell therapy**.

Other names: Foetal ventral mesencephalic cellsVentral mesencephalic tissue

Beyond the preview

Go deeper on Fetal ventral mesencephalic cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fetal ventral mesencephalic cells.

Explore the full profile